| [1] |
Huijberts I, Pinckaers F, Olthuis S, et al. Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre,open-label, randomised controlled trial in the Netherlands [J]. Lancet Neurol, 2024, 23(9): 893-900.
|
| [2] |
Thomalla G, Fiehler J, Subtil F, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial [J].Lancet Neurol, 2024, 23(9): 883-892.
|
| [3] |
Sun X, Deng Y, Zhang Y, et al. Balloon angioplasty vs medical management for intracranial artery stenosis:the BASIS randomized clinical trial [J]. JAMA, 2024, 332(13): 1059-1069.
|
| [4] |
Liu J, Zhou Y, Zhang L, et al. Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label,blinded-endpoint, randomised controlled trial [J]. Lancet, 2024, 404(10468): 2165-2174.
|
| [5] |
Gao F, Tong X, Jia B, et al. Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint,randomised controlled trial [J]. Lancet Neurol, 2024, 23(8): 797-806.
|
| [6] |
MARVEL Trial Authors for the MARVEL Investigators, Yang Q, Guo C, et al. Methylprednisolone as adjunct to endovascular thrombectomy for large-vessel occlusion stroke: the MARVEL randomized clinical trial [J]. JAMA, 2024, 331(10): 840-849.
|
| [7] |
Nogueira RG, Jovin TG, Liu X, et al. Endovascular therapy for acute vertebrobasilar occlusion (VERITAS):a systematic review and individual patient data meta-analysis [J]. Lancet, 2025, 405(10472): 61-69.
|
| [8] |
Xiong Y, Campbell B, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy [J]. N Engl J Med, 2024, 391(3): 203-212.
|
| [9] |
Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial [J]. JAMA, 2024, 332(17): 1437-1445.
|
| [10] |
Li S, Gu HQ, Li H, et al. Reteplase versus Alteplase for acute ischemic stroke [J]. N Engl J Med, 2024,390(24): 2264-2273.
|
| [11] |
Albers GW, Jumaa M, Purdon B, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection [J]. N Engl J Med, 2024, 390(8): 701-711.
|
| [12] |
Coutts SB, Ankolekar S, Appireddy R, et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial [J]. Lancet,2024, 403(10444): 2597-2605.
|
| [13] |
Adeoye O, Broderick J, Derdeyn CP, et al. Adjunctive intravenous Argatroban or Eptifibatide for ischemic stroke [J]. N Engl J Med, 2024, 391(9): 810-820.
|
| [14] |
Zhao W, Li S, Li C, et al. Effects of Tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial [J]. JAMA Neurol, 2024, 81(6): 594-602.
|
| [15] |
Goeldlin MB, Hakim A, Branca M, et al. Early vs late anticoagulation in minor, moderate, and major ischemic stroke with atrial fibrillation: post hoc analysis of the ELAN randomized clinical trial [J]. JAMA Neurol, 2024, 81(7): 693-702.
|
| [16] |
Kelly P, Lemmens R, Weimar C, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial [J]. Lancet, 2024, 404(10448):125-133.
|
| [17] |
Li J, Meng X, Shi FD, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack(CHANCE-3): multicentre, double blind, randomised, placebo controlled trial [J]. BMJ, 2024, 385:e079061.
|
| [18] |
Pradilla G, Ratcliff JJ, Hall AJ, et al. Trial of early minimally invasive removal of intracerebral hemorrhage[J]. N Engl J Med, 2024, 390(14): 1277-1289.
|
| [19] |
Beck J, Fung C, Strbian D, et al. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial [J]. Lancet, 2024, 403(10442): 2395-2404.
|
| [20] |
Liu Q, Mo S, Wu J, et al. Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label,blinded-endpoint, randomised trial [J]. Lancet Neurol, 2024, 23(12): 1195-1204.
|
| [21] |
Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for factor Ⅹa inhibitor-associated acute intracerebral hemorrhage [J]. N Engl J Med, 2024, 390(19): 1745-1755.
|
| [22] |
Guo J, Chen X, Wu M, et al. Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised,placebo-controlled, double-blind, clinical trial [J]. Lancet, 2024, 404(10468): 2187-2196.
|
| [23] |
Wessels L, Wolf S, Adage T, et al. Localized Nicardipine release implants for prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a randomized clinical trial [J]. JAMA Neurol, 2024, 81(10):1060-1065.
|
| [24] |
Ma W, Chen C, Gong Y, et al. Causal effect estimation on imaging and clinical data for treatment decision support of aneurysmal subarachnoid hemorrhage [J]. IEEE Trans Med Imaging, 2024, 43(8): 2778-2789.
|
| [25] |
Truckenmueller P, Wolf S, Wasilewski D, et al. Association of fluid balance and hemoglobin decline with neurological outcome after aneurysmal subarachnoid hemorrhage [J]. Crit Care Med, 2024, 52(9):1391-1401.
|
| [26] |
English SW, Delaney A, Fergusson DA, et al. Liberal or restrictive transfusion strategy in aneurysmal subarachnoid hemorrhage [J]. N Engl J Med, 2024. Online ahead of print.
|
| [27] |
Turgeon AF, Fergusson DA, Clayton L, et al. Liberal or restrictive transfusion strategy in patients with traumatic brain injury [J]. N Engl J Med, 2024, 391(8): 722-735.
|
| [28] |
Yen HC, Chuang HJ, Hsiao WL, et al. Assessing the impact of early progressive mobilization on moderate-to-severe traumatic brain injury: a randomized controlled trial [J]. Crit Care, 2024, 28(1): 172.
|
| [29] |
Ko YC, Lin HY, Huang EP, et al. Intraosseous versus intravenous vascular access in upper extremity among adults with out-of-hospital cardiac arrest: cluster randomised clinical trial (VICTOR trial) [J]. BMJ,2024, 386: e079878.
|
| [30] |
Nutma S, Beishuizen A, van den Bergh WM, et al. Ghrelin for neuroprotection in post-cardiac arrest coma:a randomized clinical trial [J]. JAMA Neurol, 2024, 81(6): 603-610.
|
| [31] |
中国医师协会神经外科医师分会神经电生理监测学组, 中国研究型医院学会临床神经电生理专委会,中国人体健康科技促进会重症脑损伤专业委员会. 神经重症患者的神经电生理监测与评估专家共识(2024版) [J]. 中华医学杂志, 2024, 104(23): 2113-2122.
|
| [32] |
Li G, Lin Y, Yang J, et al. Intensive ambulance-delivered blood-pressure reduction in hyperacute stroke [J].N Engl J Med, 2024, 390(20): 1862-1872.
|
| [33] |
Greer DM, Helbok R, Badjatia N, et al. Fever prevention in patients with acute vascular brain injury: the INTREPID randomized clinical trial [J]. JAMA, 2024, 332(18): 1525-1534.
|
| [34] |
Lavinio A, Coles JP, Robba C, et al. Targeted temperature control following traumatic brain injury:ESICM/NACCS best practice consensus recommendations [J]. Crit Care, 2024, 28(1): 170.
|
| [35] |
American College of Surgeons. Best practices guidelines in the management of traumatic brain injury [EB/OL]. (2024-10-29) [2025-01-13].https://www.facs.org/media/vgfgjpfk/best-practices-guidelines-traumatic-brain-injury.pdf.
|
| [36] |
中国卒中学会, 《中国卒中学会急性缺血性卒中再灌注治疗指南2024》编写组. 中国卒中学会急性缺血性卒中再灌注治疗指南2024 [J]. 中国卒中杂志, 2024, 19(12): 1459-1477.
|
| [37] |
中国残疾人康复协会神经康复专业委员会, 中国康复研究中心. 神经重症气管切开患者气道功能康复与管理专家共识 (2024) [J]. 中国康复理论与实践, 2024, 30(8): 869-881.
|
| [38] |
陈雨晴, 王淑雅, 张琳琳, 等. 2022～2023年神经重症进展与展望 [J]. 中国急救医学, 2024, 44(1):30-37.
|